LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Immunoassay, Mini Mass Spec Combined for Malaria Detection

By LabMedica International staff writers
Posted on 01 Nov 2022
Print article
Image: The Continuity transportable mass spectrometer brings high-sensitivity and large mass range to chemical analysis in the field (Photo courtesy of BaySpec)
Image: The Continuity transportable mass spectrometer brings high-sensitivity and large mass range to chemical analysis in the field (Photo courtesy of BaySpec)

Currently, several different technologies are available for diagnosing malaria, but each has drawbacks. PCR, for instance, is highly sensitive and specific, but it requires upfront sample processing and specialized equipment. While point-of-care and home PCR testing has come to market in recent years, these assays are quite expensive.

There are also rapid antigen tests for malaria, but these tests can be expensive. Microscopy is the traditional gold standard for diagnosing malaria, but it is labor intensive and subjective as well as technically challenging. A protein detection workflow that combines paper-based immunoassays with miniaturized mass spectrometry to enable diagnostic testing in resource-constrained areas has been developed.

Biochemists at Ohio State University (Columbus, OH, USA) used ionic probe technology for malaria detection and suggested it could be applied for large-scale surveillance and screening for the disease. The probes provide a more stable alternative to reagents used in conventional immunoassays, making them potentially useful for work in areas where cold storage is not widely available. The probes remain stable for several weeks under ambient conditions and are designed to release, upon treatment with ammonium hydroxide, mass tags that can be detected using paper spray ionization mass spectrometry.

The investigators synthesized pH-sensitive ionic probes and coupled them with monoclonal antibodies specific to the Plasmodium falciparum histidine-rich protein 2 (PfHRP2) malaria antigen. They then used the antibody-ionic probe conjugates in a paper-based immunoassay to capture PfHRP2 antigen from untreated whole blood. After the immunoassay, the bound ionic probes were cleaved, and the released mass tags were analyzed through an on-chip paper spray mass spectrometry strategy.

The test was able to detect the malaria antigen PfHRP2 in untreated human serum at levels down to 0.216 nmol/L, below the 0.227 nmol/L sensitivity threshold recommended by the World Health Organization for evaluating symptomatic patients. In terms of cost, the test is currently more expensive than the low end of the rapid antigen market, but it is expected costs will come down once the test is fully developed and being manufactured at scale. The team used a Continuity miniature mass spectrometer (BaySpec, Jose, CA, USA).

Abraham Badu-Tawiah, PhD, a Professor of Chemistry and senior author of the study, said, “Bigger mass spectrometers need to run continuously to maintain performance. Not so with portable instruments. The portable mass spectrometer is robust and can be turned it off when not in use, and turn it on when needed. It takes only 10 minutes to get it ready for analysis.”

The authors concluded that the stability and sensitivity of the developed paper-based immunoassay platform will allow miniature mass spectrometers to be used for point-of-care malaria detection as well as in large-scale surveillance screening to aid eradication programs. The study was published on October 4 2022 in the journal Analytical Chemistry.

Related Links:
Ohio State University
BaySpec 

Gold Member
Flocked Fiber Swabs
Puritan® Patented HydraFlock®
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Myeloperoxidase Assay
IDK MPO ELISA
New
Toxoplasma Gondii Immunoassay
Toxo IgM AccuBind ELISA Kit

Print article

Channels

Molecular Diagnostics

view channel
Image: The Mirvie RNA platform predicts pregnancy complications months before they occur using a simple blood test (Photo courtesy of Mirvie)

RNA-Based Blood Test Detects Preeclampsia Risk Months Before Symptoms

Preeclampsia remains a major cause of maternal morbidity and mortality, as well as preterm births. Despite current guidelines that aim to identify pregnant women at increased risk of preeclampsia using... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Microbiology

view channel
Image: The lab-in-tube assay could improve TB diagnoses in rural or resource-limited areas (Photo courtesy of Kenny Lass/Tulane University)

Handheld Device Deliver Low-Cost TB Results in Less Than One Hour

Tuberculosis (TB) remains the deadliest infectious disease globally, affecting an estimated 10 million people annually. In 2021, about 4.2 million TB cases went undiagnosed or unreported, mainly due to... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Sekisui Diagnostics UK Ltd.